Cost-effectiveness of different strategies with biologics for the treatment of moderate to severe Crohn’s disease in China

doi:10.3748/wjg.v32.i8.115291

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 32, Issue 8

This Article

(50)

(51)

(1)

(0)

(1)

(1253)

(1)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Observational Study

World J Gastroenterol. Feb 28, 2026; 32(8): 115291
Published online Feb 28, 2026. doi: 10.3748/wjg.v32.i8.115291

Table 4 Summary of net monetary benefit and incremental cost-effectiveness ratio results comparing different biologic sequences for biologic-exposed Crohn’s disease patients

Sequence	Costs ($)	QALY	Net monetary benefit ($)	Incremental costs ($)	Incremental QALYs	Incremental cost-effectiveness ratio ($/QALY)¹
Sequence 1: VDZ-UST	21375.37	3.848	30363.95	-	-	-
Sequence 3: ADA-UST	20813.64	3.865	31150.98	-561.73	0.017	-33520.57
Sequence 5: ADA-VDZ	20304.88	3.664	28962.46	-1070.49	-0.184	5822.22
Sequence 6: UST-VDZ	21899.71	3.852	29883.92	524.34	0.003	159090.08
Sequence 13: ADA-UST-VDZ	23620.33	3.924	29137.76	2244.97	0.076	29626.51
Sequence 14: ADA-VDZ-UST	23714.52	3.921	28995.66	2339.16	0.072	32392.94
Sequence 15: UST-VDZ-ADA	23814.60	3.927	28983.03	2439.23	0.079	30987.73
Sequence 16: VDZ-ADA-UST	23315.89	3.920	29393.93	1940.52	0.072	26882.61
Sequence 17: VDZ-UST-ADA	23291.21	3.924	29462.02	1915.84	0.075	25404.50

¹Compared to sequence 1 (vedolizumab-ustekinumab).

ADA: Adalimumab; QALYs: Quality-adjusted life years; UST: Ustekinumab; VDZ: Vedolizumab.

Full Size Table

Citation: Wu Y, Tao LB, Liu C, Wang FX, Yan Y, Sun S. Cost-effectiveness of different strategies with biologics for the treatment of moderate to severe Crohn’s disease in China. World J Gastroenterol 2026; 32(8): 115291
URL: https://www.wjgnet.com/1007-9327/full/v32/i8/115291.htm
DOI: https://dx.doi.org/10.3748/wjg.v32.i8.115291

Wu Y, Tao LB, Liu C, Wang FX, Yan Y, Sun S. Cost-effectiveness of different strategies with biologics for the treatment of moderate to severe Crohn’s disease in China. World J Gastroenterol 2026; 32(8): 115291 [PMID: 41809880 DOI: 10.3748/wjg.v32.i8.115291]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.